eTable 2. Evidence for treatment with intranasal topical corticoids in sinunasal olfactory dysfunction caused by chronic rhinosinusitis with polyposis (RCT).
| Author | Study participants | Clinical endpoint | Results |
|
Xu et al., 2020 (e92) |
n = 127 1) Methylprednisolone 24 mg + budesonide NS for 1 week 2) Budesonide nasal drops + budesonide NS for 1 week 3) Budesonide NS for 1 week |
VAS (0–10) | Significant VAS improvement in all groups compared with baseline No difference between the groups |
|
Zeng et al., 2019 (e93) |
n = 187* 1) Fluticasone propionate NS for 3 months 2) Clarithromycin 250 mg for 3 months |
VAS (0–10) | Significant VAS improvement in both groups compared with baseline No difference between the groups |
|
Khan et al., 2019 (e94) |
n = 310 1) Mometasone furoate NS 1/d 2) Mometasone furoate NS 2/d 3) Placebo |
Subjective assessment (0–3) | Significant improvement compared with baseline only for 2 × daily nasal spray |
|
Zhou et al., 2016 (e95) |
n = 748 1) Mometasone furoate NS 2/d for 16 weeks 2) Placebo mometasone furoate |
Subjective assessment (0–3) | Significant improvement compared with placebo |
|
Bangwala et al., 2014 (e64) |
n = 419 Review: 28 RCT Meta-analysis: 5 RCT |
Subjective assessment (0–3) Objective testing |
Significant improvement of olfaction by oral and topical steroids (improvement in 70% of the topical studies) |
|
Jankowski et al., 2009 (e96) |
n = 246 1) Fluticasone propionate NS 2/d for 8 months 2) Fluticasone propionate NS 2/d for 1 month, Fluticasone propionate NS 1/d + placebo NS for 7 months 3) Placebo NS for 2 months, then fluticasone propionate NS 2/d for 6 months |
VAS (0–100) Mean sense of smell disorder score |
Significant improvement of both scores in corticoid groups compared with placebo |
|
Ehnhage et al., 2009 (e97) |
n = 68 1) Fluticasone propionate nasal drops for 10 weeks 2) Placebo for 10 weeks |
Subjective assessment (0–3) Butanol threshold test |
No significant improvement compared with placebo |
|
Small et al., 2008 (e98) |
n = 447 1) Mometasone furoate NS for 4 months 2) Placebo |
Subjective assessment (0–3) | Significant improvement compared with placebo |
*Also included patients who had chronic rhinosinusitis without polyposis
NS, Nasal spray; RCT, randomized controlled trial; VAS, visual analog scale